University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

Public Health Resources

Public Health Resources

6-1-2019

IFN- Γ : A cytokine at the right time, is in the right place

J. Daniel Burke

Leidos Inc.

Howard A. Young

National Cancer Institute at Frederick, younghow@mail.nih.gov

Follow this and additional works at: <https://digitalcommons.unl.edu/publichealthresources>

Part of the [Medical Sciences Commons](#), and the [Public Health Commons](#)

Burke, J. Daniel and Young, Howard A., "IFN- Γ : A cytokine at the right time, is in the right place" (2019). *Public Health Resources*. 581.

<https://digitalcommons.unl.edu/publichealthresources/581>

This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Review

IFN- γ : A cytokine at the right time, is in the right placeJ. Daniel Burke^{a,*}, Howard A. Young^b^a AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA^b Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA

ARTICLE INFO

Keywords:

Interferon gamma
Tumor microenvironment
IL-12
Immunotherapy
Immunosuppression

ABSTRACT

Interferon gamma has long been studied as a critical mediator of tumor immunity. In recent years, the complexity of cellular interactions that take place in the tumor microenvironment has become better appreciated in the context of immunotherapy. While checkpoint inhibitors have dramatically improved remission rates in cancer treatment, IFN- γ and related effectors continue to be identified as strong predictors of treatment success. In this review, we provide an overview of the multiple immunosuppressive barriers that IFN- γ has to overcome to eliminate tumors, and potential avenues for modulating the immune response in favor of tumor rejection.

1. Introduction

In recent years, we have witnessed enormous growth in the application of immunotherapy to treat various malignancies. Extending from a standard of surgery, chemo- and radiation therapies, remarkable improvements in response rates have been observed through the application of various antibody [1,2] and cell based therapies [3–5]. A major contributing factor to the efficacy of these treatments is mediated by the secretion of cytokines which activate and instruct cells of the immune system, as well as exert direct cytotoxic effects on tumor cells themselves. It was a consequence of the highly potent effects exerted by cytokines that they were first explored as treatments for different malignancies. The earliest FDA approved cytokine treatment was recombinant Interleukin-2 (IL-2), which arose from clinical trials demonstrating responses in renal cell carcinoma (RCC) and metastatic melanoma [6]. However, despite promising responses, these therapies encountered severe toxicities which curbed their acceptance as a viable therapy. Indeed, given the broad cytokine-sensitivity of cells spread throughout the body, including cells of hematopoietic and non-hematopoietic origin, systemic administration of cytokines is not well tolerated due to acute [7,8] and chronic adverse events [9,10]. Recognizing the challenges of systemic toxicity, efforts were undertaken to localize the delivery of cytokines, and to better understand the immunological activity of cells found within the tumor [11,12]. It was appreciated early on, that a good correlation existed between the antitumor activity of tumor infiltrating lymphocytes (TILs), and their capacity to secrete IFN- γ [13–15]. In very early adoptive cell therapy trials, transfusion of *ex vivo* expanded TILs and treatment with systemic IL-2 produced regression of tumors, and this was suspected to be a

function of IFN- γ secretion [13,16]. Attempts at exploiting the potency of IFN- γ have yielded conflicting results, with both anti- and pro-tumorigenic effects being observed. Unfortunately, intravenous or subcutaneous administration of IFN- γ has not improved the outcome of melanoma [17], renal cell carcinoma [18], leukemia [19], pancreatic carcinoma [20], breast cancer [21], and colon cancer [22].

2. IFN-gamma biology

Following its discovery in 1965 as a soluble antiviral factor released by phytohemagglutinin-stimulated PBMC [23], Interferon gamma (IFN- γ) became well known for its pleiotropic immunomodulatory effects on both innate and adaptive immunity. As a soluble homodimer [24], IFN- γ has been shown to be secreted primarily by activated lymphocytes such as CD4 and CD8 T cells [25,26], gamma delta T cells [27], as well as NK [28,29] and NK T cells [30]. Additional sources include B cells [31–34] and antigen presenting cells (macrophages [35], monocytes [36] and dendritic cells [37]). IFN- γ signals through a heterodimer of IFN γ R1/2, whose expression is broadly distributed among hematopoietic and non-hematopoietic cells alike [38]. Signaling is tightly regulated through controlled expression of IFN γ R2 with stable expression of IFN γ R1 among different cells [39,40]. This differential regulation of receptor subunits is thought to influence the balance between the mitogenic and growth inhibitory effects of IFN- γ [41]. Numerous antitumor effects of IFN- γ have been described, and include the regulation of antigen presentation, promotion of inflammatory and chemotactic signals [42,43], activation and polarization of responding leukocytes, as well as direct antiproliferative [44–46] and anti-angiogenic effects [47] (Fig. 1). Induction of angiostatic chemokines,

* Corresponding author.

E-mail address: jdandburke@gmail.com (J.D. Burke).<https://doi.org/10.1016/j.smim.2019.05.002>

Received 9 May 2019; Accepted 15 May 2019

Available online 17 June 2019

1044-5323/© 2019 Elsevier Ltd. All rights reserved.

Fig. 1. IFN- γ exerts pleiotropic effects to overcome tumor immunosuppression. The tumor microenvironment exerts strong antagonism toward infiltrating lymphocytes through various cytokine, receptor and metabolic processes. To overcome these pathogenic barriers, IFN- γ and IL-12 operate in concert to amplify an anti-tumoral response through dampening immunosuppressive signals and increasing cytolytic effector function and direct antiproliferative signals.

CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 (I-TAC) by IFN- γ block neovascularization and also recruit effector leukocytes [48–50]. IFN- γ also antagonizes suppressive cytokine expression (TGF- β , IL-10), and favors the induction of IL-12 expression in macrophages [51,52]. IFN- γ signaling is able to repress tumorigenic M2-differentiation of macrophages [53]. Proapoptotic effects have also been attributed to IFN- γ [54,55]. Induction of TRAIL and its cognate receptor, a potent mediator of apoptosis in tumor cells, is also upregulated by IFN- γ [56,57]. Direct induction of caspase-1 and -8 in tumor cells by IFN- γ is also an effective inducer of apoptosis [58,59]. Tumor cell apoptosis is also induced through upregulation of Fas and FasL [60,61]. Generation of reactive oxygen species and nitric oxide are potent cytotoxic effectors that are also regulated by IFN- γ [62,63].

Secretion of IFN- γ by tumor infiltrating lymphocytes (TILs) results in the upregulation of antigen presentation in dendritic cells and macrophages [42,64]. IFN- γ also upregulates specific components of the immunoproteasome thereby producing unique peptides for MHC-I presentation [65–67]. In macrophages and dendritic cells, IFN- γ upregulates MHC-II expression through activation of MHC class II transactivator (CIITA) [68,69]. Acting on APC, IFN- γ upregulates expression of costimulatory molecules and cytokines which are necessary for activation of T cells [70]. In tumor cells, IFN- γ also induces the expression of MHC-I and STAT1 associated cyclin dependent kinase resulting in apoptosis of tumor cells and immune recognition [47,71]. Underscoring the requirement for IFN- γ in eliminating tumors, many studies have utilized various genetic and antibody blocking approaches to demonstrate both the direct [72,73] and indirect [74] aspects of IFN- γ -mediated tumor suppression.

Contrary to the many antitumorigenic effects exerted by IFN- γ , protumoral effects have also been observed. This activity is thought to occur primarily through a loss of IFN- γ signaling sensitivity, reduced antigen presentation [75] and induction of indolamine 2, 3-dioxygenase (IDO) [76] and checkpoint inhibitors [77]. Resistance to IFN- γ mediated cytotoxicity and cytoxicity can be mediated by mutations in JAK-STAT signaling and antigen processing proteins [78–80]. A loss of

IFN- γ signaling reduces MHC-I induction. Additionally, tumor-associated methylation of the IFN- γ promoter reduces MHC-I expression in tumors tissues [81]. The loss of IFN- γ responsiveness in tumors is associated with lower antigenicity [72]. Along with the aberrant expression of the coinhibitory molecule, PD-L1, in tumor tissues [82,83], its expression is also induced through exposure to IFN- γ [84,85]. Interestingly, the duration of IFN- γ exposure also dictates the responsiveness of tumors to immune suppression, with chronic exposure producing a loss of sensitivity known as “adaptive resistance” [77].

3. IL-12 biology

A major inducer of IFN- γ is IL-12, and the expression of both genes is coordinated (i.e. IL-12 induces IFN- γ , and IFN- γ induces IL-12). IL-12 exerts potent immunomodulatory effects of cells of innate and adaptive immunity. Secreted as a biologically active 70 kDa heterodimer, IL-12 is composed of disulfide linked alpha (p35) and beta (p40) subunits [86]. Binding to its cognate heterodimeric IL12RB1/2 receptor induces signaling via Jak-mediated phosphorylation of STAT4 [87,88]. Signaling through STAT4 induces the expression of IFN- γ [89] (Fig. 1). During the activation of naïve CD8 T cells, IL-12 provides a third signal, alongside TCR and CD28 costimulation which improves clonal expansion and cytolytic activity [90,91]. Proliferative responses to IL-12 can be influenced by induction of CD25, a necessary component of IL-2 signaling [92]. Other significant effects of IL-12 include the induction of T cell, NK and NK T cell cytolytic activity, and enhanced antigen presentation [93]. Many of the IL-12 mediated effects are exerted through inducible IFN- γ expression and the skewing of CD4 T cells to a Th1 phenotype [94,95]. Induction of IFN- γ in T cells initiates a positive feedback loop whereby IFN- γ sensitive APCs are primed to produce additional IL-12 [96]. Synergy between IL-12 and IL-18 has also been demonstrated to strongly induce IFN- γ in B cells [33,34]. IL-12, and other cytokines have been shown to enhance the CTL activity of T cells through increasing the sensitivity to weak or self antigens [97,98]. This has been one explanation for the development of autoimmunity

developing during microbial infections, as there is often an abundance of IL-12 present at the site of infection [99]. IL-12 is mainly produced by APCs (dendritic cells, monocytes, macrophages and B cells) and can be activated by various TLR signals. This effect is currently being explored as a potential mechanism to boost anti-tumor immunity [100–103]. However, opposing effects have also been observed where TLR ligands can promote a tolerogenic response in DCs through the upregulation of IL-10 and TGF- β [104]. Signals that inhibit IL-12 production include IL-10 and TGF- β , and these same signals also inhibit IFN- γ [105,106].

4. Tumor microenvironment

As our understanding of tumor immunology has advanced, we have appreciated that various malignancies exert profoundly suppressive cues toward anti-tumor immune cells [107–110] (Fig. 1). The tumor microenvironment, once formed, is a formidable obstacle for innate and adaptive immunity to overcome. Prominent barriers to elimination include the tumor promoted conditioning of immunosuppressive cells such as T_{reg}, MDSC and M2-macrophages, as well as limited antigen presentation, upregulation of T cell suppressive signals (e.g. PD-1/L1 and CTLA-4) and metabolic cues.

One prominent inhibitory molecule that is produced in tumors, and is associated with poor outcome, is IL-10, a potent anti-inflammatory cytokine [111,112]. Within the tumor microenvironment, tumor cells themselves have been shown to express IL-10 [113,114] in addition to infiltrating hematopoietic cells of myeloid [115] and lymphoid origin [116]. Regulatory CD4 T cells (T_{reg}) are also significant sources of IL-10 in tumors, and their presence in high proportion relative to CD8 T cells is indicative of poor prognosis [117–119]. Opposing effects of IL-10 have been observed, where a decrease in antigen presentation is detected in CD4 T cells [120,121] and macrophages, and a stimulatory effect is observed in CD8 T cells [122–125]. Cross-regulation between cytokines has been shown to exist between IL-10 and IFN- γ [126]. Depending on the timing and magnitude of expression, both cytokines can interfere with one another. IL-10 has been clearly shown to mitigate the effects of IFN- γ in antigen presentation through down regulation of MHC-II, costimulatory molecules and proteolytic enzymes [127–132]. This effect is mediated by interference with IFN- γ signaling through the Jak-STAT and NF κ B transcriptional pathways [133,134]. In macrophages, IL-10 mediates downregulation of costimulatory molecules and MHC-II through the induction of March-1, an E3 ubiquitin ligase, which specifically targets these critical molecules for proteolytic degradation [135]. Mirrored in T cells, IL-10 also inhibits tyrosine phosphorylation and activation of CD28 [136]. IFN- γ exerts a strong antagonism towards IL-10 through transcriptional suppression [137]. Suppression of IL-10 in CpG-stimulated DCs was accompanied by a strong induction of IL-12 expression [138]. A number of studies have also provided evidence for the suppressive effect of IFN- γ towards T_{reg} stability [32,139,140].

Another contributor to tumor immunosuppression is myeloid derived suppressive cells (MDSC), which are activated through inflammatory processes and serve to dampen immune responses. MDSC secrete various immunosuppressive molecules including arginase (ARG1), iNOS-2, TGF- β , IL-10, COX2 and indoleamine 2, 3-dioxygenase (IDO) which sequesters tryptophan and decreases L-selectin expression on T cells [141–144] (Fig. 1). Of interest is the fact that IFN- γ induces many of these genes, thus its actions enhance the host immune response but also damped the response if IFN- γ signaling is prolonged. Both arginase and iNOS2 utilize L-arginine as a substrate, and thus deplete its availability to T cells, which limits their functional capacity. Surface expression of ADAM17 on MDSC cleaves L-selectin (CD62L) and interferes with homing to lymph nodes [145]. Production of ROS can interfere directly with TCR activation and chemokine activity through protein nitration [146,147] (Fig. 1). In macrophages, nitration of STAT1 has also been suggested to limit IFN- γ inducible signaling [148]. Additionally, MDSC promote tumorigenesis through expression

of VEGF, bFGF, Bv8 and MMP9 which have been shown to be angiogenic [149,150].

Tumor-associated macrophages are another significant leukocyte population commonly found in tumors, and can be generally defined by their pro- or anti-inflammatory function [151,152]. Pro-inflammatory M1-type macrophages can suppress tumor growth through production of IL-1, IL-6, IL-12, TNF- α and upregulation of antigen presentation and costimulatory molecule expression [153]. Their development is promoted by the presence of IFN- γ , GM-CSF or LPS [154]. In contrast, anti-inflammatory M2-type macrophages produce abundant IL-4, IL-10, TGF- β , prostaglandin E2 and VEGF which favor tumorigenesis. Environmental factors which influence the development of M2-type macrophages include tumor secreted IL-4, IL-13, IL-10 and M-CSF [152]. Additionally, their development is also favored by exposure to lactic acid and contact with apoptotic cells or damage-associated molecular patterns (DAMPs) which are distributed through tumor tissue [155,156]. The presence of M2-type macrophages is correlated with poor prognosis in a variety of malignancies [157,158].

Co-inhibitory molecules are normally upregulated on activated T cells following stimulation. These signals serve to limit excessive inflammation, and exert negative feedback. In animals lacking co-inhibitory molecules, or during administration of checkpoint inhibitors in the clinic, autoimmune-like pathologies have been documented [159]. However, in tumors, these regulatory mechanisms limit the development of a robust response. Consequently, a number of co-inhibitory signaling molecules (PD-1/L1, CTLA-4 and others) have been investigated in the context of boosting anti-tumoral immunity [160,161]. The expression of these markers correlates well with the degree of unresponsiveness. PD-1 is expressed on the surface of activated T cells, and directly attenuates CD28-mediated signaling through the recruitment of phosphatases to TCR-proximal signaling complexes [162] (Fig. 1). CTLA-4 is also upregulated on the surface of activated T cells, but interferes with CD28 costimulation through distinct mechanisms from PD-1 [162,163]. During chronic viral infection, or in tumors, where persistent exposure to antigen can occur, the degree to which T cells are stimulated with antigen, corresponds with their loss of functional capacity [164]. Continual TCR signaling leads to a reduced rate of remethylation at the PD-1 locus, thereby reinforcing expression and potentiating inhibitory effects [165]. A progressive loss of proliferative capacity and IL-2 production by T cells is followed by a failure to produce TNF- α and IFN- γ . This process, termed exhaustion, is not a terminal cell fate, and can be reversed in vivo through the blockade of co-inhibitory receptors [161,166]. Indeed, FDA-approved monoclonal antibodies directed against PD-1, PD-L1 or CTLA-4 have proven effective at interfering with the immunosuppressive effects that are exerted by tumor tissues on cytotoxic T cells [167]. Additional co-inhibitory receptors such as Lag-3, Tim-3, BTLA, CD160 and 2B4 are being explored in clinical and pre-clinical development [168,169].

Another hallmark of the tumor microenvironment is dysregulated metabolism, where glucose is utilized through aerobic glycolysis instead of oxidative phosphorylation. This process, known as the Warburg effect, produces considerable secreted lactate (lactic acid) which signals through GPR81 on surrounding tumor cells to induce PD-L1 expression [170] (Fig. 1). Lactate also strongly inhibits the expression of cytolytic effectors granzyme B and IFN- γ in CD8 T cells [171]. Additionally, given the rapid consumption of glucose by tumor cells, its reduced availability limits T cell function [172]. This metabolic restriction is sensed by the metabolic enzyme and RNA binding protein, GAPDH, which, in turn, binds to the AU-rich regions of the 3' UTR of IFN- γ transcripts and reduces expression [173]. Interestingly, glucose deprivation exerts a stronger inhibitory effect on IFN- γ expression than IL-2 [174].

5. Overcoming immunosuppression

With increasing usage of checkpoint inhibitors, our understanding

of their mechanistic role in facilitating immune-mediated tumor clearance is becoming better understood. Certainly, an IFN- γ -associated gene signature was shown to be necessary for clinical benefit during PD-L1 blockade [175]. In a recent structural study of IFN γ R activation, Mendoza et al. identified synthetic IFN- γ mimetics that were able to specifically activate signaling to upregulate MHC-I expression in tumor cell lines, without upregulating the immunosuppressive molecule, PD-L1 [176]. This decoupling of immunostimulatory and immunosuppressive effects certainly opens exciting possibilities for development. A recent study by Garris et al. highlighted the critical function of PD-1 blockade in enabling the amplification of IL-12 and IFN- γ reciprocal regulation to permit an effective anti-tumoral response [177]. In the context of adoptive T cell therapy, *ex vivo* activation and expansion of T cells in the presence of IL-12 has improved CTL activity [178–180]. This effect has been attributed to dampening the negative regulatory effects exerted by IFN- γ . Specifically, a reduction of PD-1 expression in T cells limited the suppressive effects of IFN- γ -inducible PD-L1 expression in tumor tissues. Additionally, a decrease in IFN- γ R2 expression on expanded T cells also reduced the negative autocrine effects of IFN- γ expression [181].

Given the importance of IL-12 in augmenting IFN- γ expression, and the cytolytic activity of T cells, its incorporation into immunotherapy regimens is still being pursued with emphasis on targeted delivery. Systemic administration of IL-12 has shown limited success, with numerous adverse events being observed in clinical trials, likely a consequence of off-target effects, as well as poor pharmacokinetics [182–184]. To target IL-12 expression to the tumor microenvironment, plasmids encoding IL-12 have been introduced via electroporation [185,186], intratumoral injection of viral vectors encoding IL-12 [187], engineered tumor-specific T cells expressing IL-12 [188–195] and intratumoral injection of microspheres containing slow-release IL-12 [196,197]. Recent attention has been given to an IL-12-fused anti-histone antibody (NHS-IL12) which targets sites of cell necrosis where free cellular DNA is abundant. When combined with radiation therapy in a mouse model, a significant anti-tumor immune response was observed alongside increased survival [198,199]. More recently, in a phase I clinical trial, NHS-IL12 was well tolerated, and was accompanied by an indication of anti-tumor immunity [200].

6. Conclusions

Coupled with an increasingly sophisticated understanding of anti-tumor immunity, the powerful tools of molecular immunology are allowing us to develop innovative new therapies to treat cancer. We have already seen encouraging improvements in potency of immunotherapy, and it is clear that many targets still exist for intervention. Given the complexity of tumor-mediated immunosuppression, it is very likely that integrating multiple facets of tumor immunity will be necessary to overcome the existing barriers. The pleiotropic nature of IFN- γ underscores this, and certainly maintains it as an attractive candidate for development, despite previous challenges. To better reflect a natural mechanism of localized activity, it is critical that the delivery of the right treatment is to the right place. Indeed, the continued honing of immunotherapy will undoubtedly yield more effective and better tolerated therapies in the clinic.

References

- [1] S.L. Topalian, C.G. Drake, D.M. Pardoll, Immune checkpoint blockade: a common denominator approach to cancer therapy, *Cancer Cell* 27 (2015) 450–461, <https://doi.org/10.1016/j.ccell.2015.03.001>.
- [2] D.N. Khalil, E.L. Smith, R.J. Brentjens, J.D. Wolchok, The future of cancer treatment: immunomodulation, CARs and combination immunotherapy, *Nat. Rev. Clin. Oncol.* 13 (2016) 273–290, <https://doi.org/10.1038/nrclinonc.2016.25>.
- [3] S.L. Maude, N. Frey, P.A. Shaw, R. Aplenc, D.M. Barrett, N.J. Bunin, et al., Chimeric antigen receptor T cells for sustained remissions in leukemia, *N. Engl. J. Med.* 371 (2014) 1507–1517, <https://doi.org/10.1056/NEJMoa1407222>.
- [4] M.L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, et al., Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, *Sci. Transl. Med.* 6 (2014), <https://doi.org/10.1126/scitranslmed.3008226> 224ra25–224ra25.
- [5] N. Gökbüget, D. Stanze, J. Beck, H. Diedrich, H.-A. Horst, A. Hüttmann, et al., Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation, *Blood* 120 (2012) 2032–2041, <https://doi.org/10.1182/blood-2011-12-399287>.
- [6] S.A. Rosenberg, M.T. Lotze, J.C. Yang, P.M. Aebersold, W.M. Linehan, C.A. SEIPP, et al., Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, *Ann. Surg.* 210 (1989) 474–485, <https://doi.org/10.1097/0000658-198910000-00008>.
- [7] G.K. Antony, A.Z. Dudek, Interleukin 2 in cancer therapy, *Curr. Med. Chem.* 17 (2010) 3297–3302.
- [8] J.C. Poust, J.E. Woolery, M.R. Green, Management of toxicities associated with high-dose interleukin-2 and biochemotherapy, *Anticancer Drugs* 24 (2013) 1–13, <https://doi.org/10.1097/CAD.0b013e32835a5ca3>.
- [9] J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, R.H. Blum, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684, *J. Clin. Oncol.* 14 (1996) 7–17, <https://doi.org/10.1200/JCO.1996.14.1.7>.
- [10] L.M. Schuchter, Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? *J. Clin. Oncol.* 22 (2004) 7–10, <https://doi.org/10.1200/JCO.2004.10.907>.
- [11] B.M. Vose, M. Moore, Human tumor-infiltrating lymphocytes: a marker of host response, *Semin. Hematol.* 22 (1985) 27–40.
- [12] D.S. Heo, T.L. Whiteside, A. Kanbour, R.B. Herberman, Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors, *J. Immunol.* 140 (1988) 4042–4049.
- [13] M. Prat, S. Bretti, M. Amedeo, S. Landolfo, P.M. Comoglio, Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas, *J. Immunol.* 138 (1987) 4530–4533.
- [14] R.J. Barth, Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes, *J. Exp. Med.* 173 (1991) 647–658, <https://doi.org/10.1084/jem.173.3.647>.
- [15] P.S. Goedegebuure, M. Zuber, D.L. Leonard-Vidal, U.L. Burger, J.C.J. Cusack, M.P. Chang, et al., Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy, *Surg. Oncol.* 3 (1994) 79–89.
- [16] S.L. Topalian, D. Solomon, F.P. Avis, A.E. Chang, D.L. Freerksen, W.M. Linehan, et al., Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study, *J. Clin. Oncol.* 6 (1988) 839–853, <https://doi.org/10.1200/JCO.1988.6.5.839>.
- [17] J.H. Schiller, M. Pugh, J.M. Kirkwood, D. Karp, M. Larson, E. Borden, Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design, *Clin. Cancer Res.* 2 (1996) 29–36.
- [18] M.E. Gleave, M. Elhilali, Y. Fradet, I. Davis, P. Venner, F. Saad, et al., Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma, *N. Engl. J. Med.* 338 (1998) 1265–1271, <https://doi.org/10.1056/NEJM199804303381804>.
- [19] R. Kurzrock, M. Talpaz, H. Kantarjian, R. Walters, S. Saks, J.M. Trujillo, et al., Therapy of chronic myelogenous leukemia with recombinant interferon-gamma, *Blood* 70 (1987) 943–947.
- [20] D.D. Von Hoff, T.R. Fleming, J.S. MacDonald, P.J. Goodman, J. Van Damme, T.D. Brown, et al., Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study, *J. Biol. Response Mod.* 9 (1990) 584–587.
- [21] L.T. Vahdat, D.J. Cohen, D. Zipin, K.S. Lo, D. Donovan, D. Savage, et al., Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon- γ after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer, *Bone Marrow Transplant.* 40 (2007) 267–272, <https://doi.org/10.1038/sj.bmt.1705692>.
- [22] M. Wiesenfeld, M.J. O'Connell, H.S. WIEAND, N.J. GONCHOROFF, J.H. DONOHUE, R.J. FITZGIBBONS, et al., Controlled clinical-trial of interferon-gamma as postoperative surgical adjuvant therapy for colon-cancer, *J. Clin. Oncol.* 13 (1995) 2324–2329, <https://doi.org/10.1200/JCO.1995.13.9.2324>.
- [23] E.F. Wheelock, Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin, *Science* 149 (1965) 310–311, <https://doi.org/10.1126/science.149.3681.310>.
- [24] J.A. Langer, A. Rashidbaigi, G. Garotta, E. Kempner, Radiation inactivation of human gamma-interferon: cellular activation requires two dimers, *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 5818–5822.
- [25] T. Kasahara, J.J. Hooks, S.F. Dougherty, J.J. Oppenheim, Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets, *J. Immunol.* 130 (1983) 1784–1789.
- [26] H. Matsushita, A. Hosoi, S. Ueha, J. Abe, N. Fujieda, M. Tomura, et al., Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN- γ dependent cell-cycle arrest, *Cancer Immunol. Res.* 3 (2015) 26–36, <https://doi.org/10.1158/2326-6066.CIR-14-0098>.
- [27] Y. Gao, W. Yang, M. Pan, E. Scully, M. Girardi, L.H. Augenlicht, et al., Gamma delta T cells provide an early source of interferon gamma in tumor immunity, *J. Exp. Med.* 198 (2003) 433–442, <https://doi.org/10.1084/jem.20030584>.
- [28] J. Yu, M. Wei, B. Becknell, R. Trotta, S. Liu, Z. Boyd, et al., Pro- and anti-inflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells, *Immunity* 24 (2006) 575–590, <https://doi.org/10.1016/j.immuni.2006.03.016>.
- [29] M.A. Cooper, T.A. Fehniger, S.C. Turner, K.S. Chen, B.A. Ghaheri, T. Ghayur, et al.,

- Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset, *Blood* 97 (2001) 3146–3151.
- [30] M.C. Leite-de-Moraes, G. Moreau, A. Arnould, F. Machavoine, C. Garcia, M. Papiernik, et al., IL-4-producing NK T cells are biased towards IFN- γ production by IL-12. Influence of the microenvironment on the functional capacities of NK T cells, *Eur. J. Immunol.* 28 (1998) 1507–1515, [https://doi.org/10.1002/\(SICI\)1521-4141\(199805\)28:05<1507::AID-IMMU1507>3.0.CO;2-F](https://doi.org/10.1002/(SICI)1521-4141(199805)28:05<1507::AID-IMMU1507>3.0.CO;2-F).
- [31] D.P. Harris, S. Goodrich, A.J. Gerth, S.L. Peng, F.E. Lund, Regulation of IFN- γ production by B effector 1 cells: essential roles for T-bet and the IFN- γ receptor, *J. Immunol.* 174 (2005) 6781–6790, <https://doi.org/10.4049/jimmunol.174.11.6781>.
- [32] S.A. Olalekan, Y. Cao, K.M. Hamel, A. Finnegan, B cells expressing IFN- γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis, *Eur. J. Immunol.* 45 (2015) 988–998, <https://doi.org/10.1002/eji.201445036>.
- [33] T. Yoshimoto, H. Okamura, Y.I. Tagawa, Y. Iwakura, K. Nakanishi, Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon- γ production from activated B cells, *Proc. Natl. Acad. Sci. U. S. A.* 94 (1997) 3948–3953.
- [34] D. Durali, M.-G. de Goër de Herve, J. Giron-Michel, B. Azzarone, J.-F. Delfraissy, Y. Taoufik, In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment, *Blood* 102 (2003) 4084–4089, <https://doi.org/10.1182/blood-2003-02-0518>.
- [35] C.M. Robinson, D. O'Dee, T. Hamilton, G.J. Nau, Cytokines involved in interferon- γ production by human macrophages, *J. Innate Immun.* 2 (2009) 56–65, <https://doi.org/10.1159/000247156>.
- [36] M.D. Kraaij, E.J.F. Vereyken, P.J.M. Leenen, T.P.P. van den Bosch, F. Rezaee, M.G.H. Bejtes, et al., Human monocytes produce interferon- γ upon stimulation with LPS, *Cytokine* 67 (2014) 7–12, <https://doi.org/10.1016/j.cyt.2014.02.001>.
- [37] T. Ohteki, T. Fukao, K. Suzue, C. Maki, M. Ito, M. Nakamura, et al., Interleukin 12-dependent interferon gamma production by CD8 α lymphoid dendritic cells, *J. Exp. Med.* 189 (1999) 1981–1986.
- [38] F. Castro, A.P. Cardoso, R.M. Gonçalves, K. Serre, M.J. Oliveira, Interferon- γ at the crossroads of tumor immune surveillance or evasion, *Front. Immunol.* 9 (2018), <https://doi.org/10.3389/fimmu.2018.00847> 665–19.
- [39] A. Pernis, S. Gupta, K.J. Gollob, E. Garfein, R.L. Coffman, C. Schindler, et al., Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in TH1 cells, *Science* 269 (1995) 245–247.
- [40] E.A. Bach, S.J. Szabo, A.S. Dighe, A. Ashkenazi, M. Aguet, K.M. Murphy, et al., Ligand-induced autoregulation of IFN- γ receptor beta chain expression in T helper cell subsets, *Science* 270 (1995) 1215–1218.
- [41] F. Novelli, P. Bernabei, L. Ozmen, L. Rigamonti, A. Allione, S. Pestka, et al., Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN- γ is correlated with the differential expression of the alpha- and beta-chains of its receptor, *J. Immunol.* 157 (1996) 1935–1943.
- [42] T.N. Ellis, B.L. Beaman, Interferon- γ activation of polymorphonuclear neutrophil function, *Immunology* 112 (2004) 2–12, <https://doi.org/10.1111/j.1365-2567.2004.01849.x>.
- [43] I.S. Mauldin, N.A. Wages, A.M. Stowman, E. Wang, M.E. Smolkin, W.C. Olson, et al., Intratumoral interferon- γ increases chemokine production but fails to increase T cell infiltration of human melanoma metastases, *Cancer Immunol. Immunother.* 65 (2016) 1189–1199, <https://doi.org/10.1038/nature14404>.
- [44] J.F. Bromberg, C.M. Horvath, Z. Wen, R.D. Schreiber, J.E. Darnell, Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma, *Proc. Natl. Acad. Sci. U. S. A.* 93 (1996) 7673–7678 <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?dbfrom=pubmed&id=8755534&retmode=ref&cmd=prlinks>.
- [45] Y.E. Chin, M. Kitagawa, W.C. Su, Z.H. You, Y. Iwamoto, X.Y. Fu, Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1, *Science* 272 (1996) 719–722.
- [46] B.L. Harvat, P. Seth, A.M. Jetten, The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells, *Oncogene* 14 (1997) 2111–2122, <https://doi.org/10.1038/sj.onc.1201055>.
- [47] H. Ikeda, L.J. Old, R.D. Schreiber, The roles of IFN gamma in protection against tumor development and cancer immunoediting, *Cytokine Growth Factor Rev.* 13 (2002) 95–109.
- [48] F. Liao, R.L. Rabin, J.R. Yannelli, L.G. Koniaris, P. Vanguri, J.M. Farber, Human Mig chemokine: biochemical and functional characterization, *J. Exp. Med.* 182 (1995) 1301–1314.
- [49] A.D. Luster, P. Leder, IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo, *J. Exp. Med.* 178 (1993) 1057–1065.
- [50] K.E. Cole, C.A. Strick, T.J. Paradis, K.T. Ogborne, M. Loetscher, R.P. Gladue, et al., Interferon-inducible T cell alpha chemotactant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3, *J. Exp. Med.* 187 (1998) 2009–2021.
- [51] L. Ulloa, J. Doody, J. Massague, Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway, *Nature* 397 (1999) 710–713, <https://doi.org/10.1038/17826>.
- [52] N. Luheshi, G. Davies, E. Poon, K. Wiggins, M. McCourt, J. Legg, Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro, *Eur. J. Immunol.* 44 (2014) 162–172, <https://doi.org/10.1002/eji.201343351>.
- [53] K. Kang, S.H. Park, J. Chen, Y. Qiao, E. Giannopoulou, K. Berg, et al., Interferon- γ represses M2 gene expression in human macrophages by disassembling enhancers bound by the transcription factor MAF, *Immunity* 47 (2017), <https://doi.org/10.1016/j.immuni.2017.07.017> 235–250.e4.
- [54] L.P. Deiss, E. Feinstein, H. Berissi, O. Cohen, A. Kimchi, Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death, *Genes Dev.* 9 (1995) 15–30.
- [55] E. Meurs, K. Chong, J. Galabru, N.S. Thomas, I.M. Kerr, B.R. Williams, et al., Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon, *Cell* 62 (1990) 379–390.
- [56] R.D. Meng, W.S. El-Deiry, p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma, *Exp. Cell Res.* 262 (2001) 154–169.
- [57] K. Takeda, M.J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita, et al., Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development, *J. Exp. Med.* 195 (2002) 161–169, <https://doi.org/10.1084/jem.20011171>.
- [58] Y.E. Chin, M. Kitagawa, K. Kuida, R.A. Flavell, X.Y. Fu, Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis, *Mol. Cell. Biol.* 17 (1997) 5328–5337.
- [59] S. Fulda, K.-M. Debatin, IFN γ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway, *Oncogene* 21 (2002) 2295–2308, <https://doi.org/10.1038/sj.onc.1205255>.
- [60] X. Xu, X.Y. Fu, J. Plate, A.S. Chong, IFN- γ induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression, *Cancer Res.* 58 (1998) 2832–2837.
- [61] J.K. Lee, T.J. Sayers, A.D. Brooks, T.C. Back, H.A. Young, K.L. Komschlies, et al., IFN- γ -Dependent delay of in vivo tumor progression by fas overexpression on murine renal cancer cells, *J. Immunol.* 164 (2000) 231–239, <https://doi.org/10.4049/jimmunol.164.1.231>.
- [62] G. Berton, L. Zeni, M.A. Cassatella, F. Rossi, Gamma interferon is able to enhance the oxidative metabolism of human neutrophils, *Biochem. Biophys. Res. Commun.* 138 (1986) 1276–1282.
- [63] T. Yamashita, T. Uchida, A. Araki, F. Sendo, Nitric oxide is an effector molecule in inhibition of tumor cell growth by rIFN- γ -activated rat neutrophils, *Int. J. Cancer* 71 (1997) 223–230.
- [64] I.A. Park, S.-H. Hwang, I.H. Song, S.-H. Heo, Y.-A. Kim, W.S. Bang, et al., Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling, *PLoS One* 12 (2017) e0182786, <https://doi.org/10.1371/journal.pone.0182786.s003>.
- [65] M. Gaczynska, K.L. Rock, T. Spies, A.L. Goldberg, Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7, *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 9213–9217.
- [66] E. Pamer, P. Cresswell, Mechanisms of MHC class I-restricted antigen processing, *Annu. Rev. Immunol.* 16 (1998) 323–358, <https://doi.org/10.1146/annurev.immunol.16.1.323>.
- [67] D. Niewerth, G.J.L. Kaspers, Y.G. Assaraf, J. van Meerloo, C.J. Kirk, J. Anderl, et al., Interferon- γ -induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines, *J. Hematol. Oncol.* 7 (2014) 7, <https://doi.org/10.1186/1756-8722-7-7>.
- [68] P. Cresswell, Assembly, transport, and function of MHC class II molecules, *Annu. Rev. Immunol.* 12 (1994) 259–293, <https://doi.org/10.1146/annurev.iy.12.040194.001355>.
- [69] P.R. Wolf, H.L. Ploegh, How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway, *Annu. Rev. Cell Dev. Biol.* 11 (1995) 267–306, <https://doi.org/10.1146/annurev.cb.11.110195.001411>.
- [70] J. Pan, M. Zhang, J. Wang, Q. Wang, D. Xia, W. Sun, et al., Interferon- γ is an autocrine mediator for dendritic cell maturation, *Immunol. Lett.* 94 (2004) 141–151.
- [71] J. Gao, L.Z. Shi, H. Zhao, J. Chen, L. Xiong, Q. He, et al., Loss of IFN- γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy, *Cell* 167 (2016), <https://doi.org/10.1016/j.cell.2016.08.069> 397–404.e9.
- [72] A.S. Dighe, E. Richards, L.J. Old, R.S. Immunology, Enhanced in Vivo Growth and Resistance to Rejection of Tumor Cells Expressing Dominant Negative IFN γ Receptors, *Elsevier*, 1994 1 (1994) 447–456. doi:10.1016/1074-7613(94)90087-6.
- [73] A.S. Dighe, M.A. Farrar, R.D. Schreiber, Inhibition of cellular responsiveness to interferon-gamma (IFN gamma) induced by overexpression of inactive forms of the IFN gamma receptor, *J. Biol. Chem.* 268 (1993) 10645–10653.
- [74] D. Mumberg, P.A. Monach, S. Wanderling, M. Philip, A.Y. Toledano, R.D. Schreiber, et al., CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN- γ , *Proc. Natl. Acad. Sci. U. S. A.* 96 (1999) 8633–8638, <https://doi.org/10.1073/pnas.96.15.8633>.
- [75] G.L. Beatty, Y. Paterson, IFN- γ can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen, *J. Immunol.* 165 (2000) 5502–5508, <https://doi.org/10.4049/jimmunol.165.10.5502>.
- [76] S. Spranger, R.M. Spaapen, Y. Zha, J. Williams, Y. Meng, T.T. Ha, et al., Up-regulation of PD-L1, IDO, and tregs in the melanoma tumor microenvironment is driven by CD8+ T cells, *Sci. Transl. Med.* 5 (2013), <https://doi.org/10.1126/scitranslmed.3006504> 200ra116–200ra116.
- [77] J.L. Benci, B. Xu, Y. Qiu, T.J. Wu, H. Dada, C.T.-S. Victor, et al., Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade, (2016), pp. 1–28, <https://doi.org/10.1016/j.cell.2016.11.022>.
- [78] J.M. Zaretsky, A. Garcia-Diaz, D.S. Shin, H. Escuin-Ordinas, W. Hugo, S. Hu-Lieskovan, et al., Mutations associated with acquired resistance to PD-1 blockade in melanoma, *N. Engl. J. Med.* 375 (2016) 819–829, <https://doi.org/10.1056/NEJM.1604739>.

- NEJMoa1604958.
- [79] D.S. Shin, J.M. Zaretsky, H. Escuin-Ordinas, A. Garcia-Diaz, S. Hu-Lieskovan, A. Kalbasi, et al., Primary resistance to PD-1 blockade mediated by JAK1/2 mutations, *Cancer Discov.* 7 (2017) 188–201, <https://doi.org/10.1158/2159-8290.CD-16-1223>.
 - [80] S. Gettinger, J. Choi, K. Hastings, A. Truini, I. Datar, R. Sowell, et al., Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer, *Cancer Discov.* 7 (2017) 1420–1435, <https://doi.org/10.1158/2159-8290.CD-17-0593>.
 - [81] D. Ma, C. Jiang, X. Hu, H. Liu, Q. Li, T. Li, et al., Methylation patterns of the IFN- γ gene in cervical cancer tissues, *Sci. Rep.* 4 (2014), <https://doi.org/10.1038/srep06331> 2675–5.
 - [82] A.T. Parsa, J.S. Waldron, A. Panner, C.A. Crane, I.F. Parney, J.J. Barry, et al., Loss of tumor suppressor PTEN function increases B7-H1 expression and immune resistance in glioma, *Nat. Med.* 13 (2007) 84–88, <https://doi.org/10.1038/nm1517>.
 - [83] M. Atefi, E. Avramis, A. Lassen, D.J.L. Wong, L. Robert, D. Foulad, et al., Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma, *Clin. Cancer Res.* 20 (2014) 3446–3457, <https://doi.org/10.1158/1078-0432.CCR-13-2797>.
 - [84] H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, *Nat. Med.* 8 (2002) 793–800.
 - [85] J. Kim, A.C. Myers, L. Chen, D.M. Pardoll, Q.-A. Truong-Tran, A.P. Lane, et al., Constitutive and inducible expression of B7 family of ligands by human airway epithelial cells, *Am. J. Respir. Cell Mol. Biol.* 33 (2005) 280–289, <https://doi.org/10.1165/rcmb.2004-0129OC>.
 - [86] A.S. Stern, F.J. Podlaski, J.D. Hulmes, Y.C. Pan, P.M. Quinn, A.G. Wolitzky, et al., Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells, *Proc. Natl. Acad. Sci. U. S. A.* 87 (1990) 6808–6812.
 - [87] D.H. Presky, H. Yang, L.J. Minetti, A.O. Chua, N. Nabavi, C.Y. Wu, et al., A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits, *Proc. Natl. Acad. Sci. U. S. A.* 93 (1996) 14002–14007.
 - [88] J.S. Orange, C.A. Biron, Characterization of early IL-12, IFN- α and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection, *J. Immunol.* (1996).
 - [89] L.E. Kallal, C.A. Biron, Changing partners at the dance: variations in STAT concentrations for shaping cytokine function and immune responses to viral infections, *Jak-Stat.* 2 (2013) e23504, <https://doi.org/10.4161/jkst.23504>.
 - [90] W.R. Park, C.S. Park, M. Tomura, H.J. Ahn, Y. Nakahira, M. Iwasaki, et al., CD28 costimulation is required not only to induce IL-12 receptor but also to render janus kinases/STAT4 responsive to IL-12 stimulation in TCR-triggered T cells, *Eur. J. Immunol.* 31 (2001) 1456–1464, [https://doi.org/10.1002/1521-4141\(200105\)31:5<1456::AID-IMMU1456>3.0.CO;2-A](https://doi.org/10.1002/1521-4141(200105)31:5<1456::AID-IMMU1456>3.0.CO;2-A).
 - [91] J. Valenzuela, C. Schmidt, M. Mescher, The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells, *J. Immunol.* 169 (2002) 6842–6849, <https://doi.org/10.4049/jimmunol.169.12.6842>.
 - [92] S.H. Lee, M.F. Fragos, C.A. Biron, Cutting edge: a novel mechanism bridging innate and adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2 receptors on NK cells, *J. Immunol.* 189 (2012) 2712–2716, <https://doi.org/10.4049/jimmunol.1201528>.
 - [93] G. Trinchieri, Interleukin-12 and the regulation of innate resistance and adaptive immunity, *Nat. Rev. Immunol.* 3 (2003) 133–146, <https://doi.org/10.1038/nri1001>.
 - [94] C.Y. Wu, C. Demeure, M. Kuniwa, M. Gately, G. Delespesse, IL-12 induces the production of IFN- γ by neonatal human CD4 T cells, *J. Immunol.* 151 (1993) 1938–1949.
 - [95] S. Tugues, S.H. Burkhardt, I. Ohs, M. Vrohings, K. Nussbaum, J. vom Berg, et al., New insights into IL-12-mediated tumor suppression, *Cell Death Differ.* 22 (2014) 237–246, <https://doi.org/10.1038/cdd.2014.134>.
 - [96] D.A.A. Vignali, V.K. Kuchroo, IL-12 family cytokines: immunological playmakers, *Nat. Immunol.* 13 (2012) 722–728, <https://doi.org/10.1038/ni.2366>.
 - [97] M.A. Markiewicz, E.L. Wise, Z.S. Buchwald, E.E. Cheney, T.H. Hansen, A. Suri, et al., IL-12 enhances CTL synapse formation and induces self-reactivity, *J. Immunol.* 182 (2009) 1351–1361, <https://doi.org/10.4049/jimmunol.182.3.1351>.
 - [98] N.P. Goplen, V. Saxena, K.M. Knudson, A.G. Schrum, D. Gil, M.A. Daniels, et al., IL-12 signals through the TCR to support CD8 innate immune responses, *J. Immunol.* 197 (2016) 2434–2443, <https://doi.org/10.4049/jimmunol.1600037>.
 - [99] B.M. Segal, B.K. Dwyer, E.M. Shevach, An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease, *J. Exp. Med.* 187 (1998) 537–546, <https://doi.org/10.1084/jem.187.4.537>.
 - [100] T. Akazawa, H. Masuda, Y. Saeki, M. Matsumoto, K. Takeda, K. Tsujimura, et al., Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice, *Cancer Res.* 64 (2004) 757–764, <https://doi.org/10.1158/0008-5472.CAN-03-1518>.
 - [101] F. Gableh, M. Saeidi, S. Hemati, H. Soleimanjahi, A. Gorji, et al., Combination of the toll like receptor agonist and α -Galactosylceramide as an efficient adjuvant for cancer vaccine, *J. Biomed. Sci.* 23 (2016) 16, <https://doi.org/10.1186/s12929-016-0238-3>.
 - [102] K.-H. Pyo, Y.-W. Lee, S.M. Lim, E.-H. Shin, Immune adjuvant effect of a *Toxoplasma gondii* profilin-like protein in autologous whole-tumor-cell vaccination in mice, *Oncotarget* 7 (2016) 74107–74119, <https://doi.org/10.18632/oncotarget.12316>.
 - [103] R.T. Gazzinelli, M. Wysocka, S. Hayashi, E.Y. Denkers, S. Hieny, P. Caspar, et al., Parasite-induced IL-12 stimulates early IFN- γ synthesis and resistance during acute infection with *Toxoplasma gondii*, *J. Immunol.* 153 (1994) 2533–2543.
 - [104] H. Conroy, N.A. Marshall, K.H.G. Mills, TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours, *Oncogene* 27 (2008) 168, <https://doi.org/10.1038/sj.onc.1210910>.
 - [105] C. Du, S. Sriram, Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGF- β in ANA-1 cells, *J. Leukoc. Biol.* 64 (1998) 92–97, <https://doi.org/10.1002/jlb.64.1.92>.
 - [106] A. D'Andrea, M. Aste-Amezaga, N.M. Valiante, X. Ma, M. Kubin, G. Trinchieri, Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells, *J. Exp. Med.* 178 (1993) 1041–1048, <https://doi.org/10.1084/jem.178.3.1041>.
 - [107] D.G. Hesse, D.J. Cole, D.E. Van Epps, R.C. Williams Jr, Decreased T lymphocyte migration in patients with malignancy mediated by a suppressor cell population, *J. Clin. Invest.* 73 (1984) 1078–1085, <https://doi.org/10.1172/JCI11293>.
 - [108] M.G. Whittaker, C.G. Clark, Depressed lymphocyte function in carcinoma of the breast, *Br. J. Surg.* 58 (1971) 717–720, <https://doi.org/10.1002/bjs.1800581002>.
 - [109] D.R. McCluskey, A.D. Roy, W.P. Abram, W.M. Martin, T lymphocyte subsets in the peripheral blood of patients with benign and malignant breast disease, *Br. J. Cancer* 47 (1983) 307–309, <https://doi.org/10.1038/bjc.1983.41>.
 - [110] D.H. Munn, V. Bronte, Immune suppressive mechanisms in the tumor micro-environment, *Curr. Opin. Immunol.* 39 (2016) 1–6, <https://doi.org/10.1016/j.coi.2015.10.009>.
 - [111] D. Llopiz, M. Ruiz, L. Silva, P. Sarobe, Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10, *Front. Immunol.* 9 (2018) 525–529, <https://doi.org/10.3389/fimmu.2018.01923>.
 - [112] S. Zhao, D. Wu, P. Wu, Z. Wang, J. Huang, Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis, *PLoS One* 10 (2015) e0139598–15, <https://doi.org/10.1371/journal.pone.0139598>.
 - [113] G.A. Gastl, J.S. Abrams, D.M. Nanus, R. Oosterkamp, J. Silver, F. Liu, et al., Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression, *Int. J. Cancer* 55 (1993) 96–101.
 - [114] J. Kim, R.L. Modlin, R.L. Moy, S.M. Dubinett, T. McHugh, B.J. Nickoloff, et al., IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response, *J. Immunol.* 155 (1995) 2240–2247.
 - [115] B. Ruffell, D. Chang-Strachan, V. Chan, A. Rosenbusch, C.M.T. Ho, N. Pryer, et al., Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells, *Cancer Cell* 26 (2014) 623–637, <https://doi.org/10.1016/j.ccr.2014.09.006>.
 - [116] I. Kryczek, R. Liu, G. Wang, K. Wu, X. Shu, W. Szeliga, et al., FOXP3 defines regulatory T cells in human tumor and autoimmune disease, *Cancer Res.* 69 (2009) 3995–4000, <https://doi.org/10.1158/0008-5472.CAN-08-3804>.
 - [117] T. Saito, H. Nishikawa, H. Wada, Y. Nagano, D. Sugiyama, K. Atarashi, et al., Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers, *Nat. Med.* 22 (2016) 679–684, <https://doi.org/10.1038/nm.4086>.
 - [118] T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, *Nat. Med.* 10 (2004) 942–949.
 - [119] S. Drennan, N.D. Stafford, J. Greenman, V.L. Green, Increased frequency and suppressive activity of CD127 low/Tregs in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement, *Immunology* 140 (2013), <https://doi.org/10.1111/imm.12144> n/a–n/a.
 - [120] R. de Waal Malefyt, H. Yssel, J.E. De Vries, Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation, *J. Immunol.* 150 (1993) 4754–4765.
 - [121] R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, W. Müller, Interleukin-10-deficient mice develop chronic enterocolitis, *Cell* 75 (1993) 263–274.
 - [122] L. Wang, J.-Q. Liu, F. Talebian, Z. Liu, L. Yu, X.-F. Bai, IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4+ T cells and promoting CTL persistence in a murine model of plasmacytoma, *Oncimmunology* 4 (2015) e014232–10, <https://doi.org/10.1080/2162402X.2015.1014232>.
 - [123] A. Naing, J.R. Infante, K.P. Papadopoulos, I.H. Chan, C. Shen, N.P. Ratti, et al., PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients, *Cancer Cell* 34 (2018), <https://doi.org/10.1016/j.ccr.2018.10.007> 775–791.e3.
 - [124] J.B. Mumm, J. Emmerich, X. Zhang, I. Chan, L. Wu, S. Mauze, et al., IL-10 elicits IFN- γ -dependent tumor immune surveillance, *Cancer Cell* 20 (2011) 781–796, <https://doi.org/10.1016/j.ccr.2011.11.003>.
 - [125] H. Groux, M. Bigler, J.E. De Vries, M.G. Roncarolo, Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells, *J. Immunol.* 160 (1998) 3188–3193.
 - [126] P. Chomarat, Interferon gamma inhibits interleukin 10 production by monocytes, *J. Exp. Med.* 177 (1993) 523–527, <https://doi.org/10.1084/jem.177.2.523>.
 - [127] L.L.Y. Chan, B.K.W. Cheung, J.C.B. Li, A.S.Y. Lau, A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN- γ -induced MHC class II molecule on primary human blood macrophages, *J. Leukoc. Biol.* 88 (2010) 303–311, <https://doi.org/10.1189/jlb.1009659>.
 - [128] R. de Waal Malefyt, J. Haanen, H. Spits, M.G. Roncarolo, A. te Velde, C. Figdor, et al., Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression, *J. Exp. Med.* 174 (1991) 915–924, <https://doi.org/10.1084/jem.174.4.915>.
 - [129] D.F. Fiorentino, M.W. Bond, T.R. Mosmann, Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones, *J. Exp. Med.* 170 (1989) 2081–2095, <https://doi.org/10.1084/jem.170.6.2081>.

- [130] F. Willems, A. Marchant, J.P. Delville, C. Gerard, A. Delvaux, T. Velu, et al., Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes, *Eur. J. Immunol.* 24 (1994) 1007–1009, <https://doi.org/10.1002/eji.1830240435>.
- [131] R.S. Mitra, T.A. Judge, F.O. Nestle, L.A. Turka, B.J. Nickoloff, Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression, *J. Immunol.* 154 (1995) 2668–2677.
- [132] T. Kawamura, M. Furue, Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines, *Eur. J. Immunol.* 25 (1995) 1913–1917, <https://doi.org/10.1002/eji.1830250718>.
- [133] S. Song, H. Ling-Hu, K.A. Roebuck, M.F. Rabbi, R.P. Donnelly, A. Finnegan, Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes, *Blood* 89 (1997) 4461–4469.
- [134] S. Ito, P. Ansari, M. Sakatsume, H. Dickensheets, N. Vazquez, R.P. Donnelly, et al., Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1, *Blood* 93 (1999) 1456–1463.
- [135] S.K. Mittal, K.-J. Cho, S. Ishido, P.A. Roche, Interleukin 10 (IL-10)-mediated immunosuppression, *J. Biol. Chem.* 290 (2015) 27158–27167, <https://doi.org/10.1074/jbc.M115.682708>.
- [136] A. Joss, M. Akdis, A. Faith, K. Blaser, C.A. Akdis, IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway, *Eur. J. Immunol.* 30 (2000) 1683–1690, [https://doi.org/10.1002/1521-4141\(200006\)30:6<1683::AID-IMMU1683>3.0.CO;2-A](https://doi.org/10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A).
- [137] X. Hu, P.K. Paik, J. Chen, A. Yarinina, L. Kockeritz, T.T. Lu, et al., IFN- γ suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins, *Immunity* 24 (2006) 563–574, <https://doi.org/10.1016/j.immuni.2006.02.014>.
- [138] R.R. Flores, K.A. Diggs, L.M. Tait, P.A. Morel, IFN- γ negatively regulates CpG-Induced IL-10 in bone marrow-derived dendritic cells, *J. Immunol.* 178 (2006) 211–218, <https://doi.org/10.4049/jimmunol.178.1.211>.
- [139] J.H. Lee, C. Elly, Y. Park, Y.-C. Liu, E3 ubiquitin ligase VHL regulates hypoxia-inducible factor-1 α to maintain regulatory T cell stability and suppressive capacity, *Immunity* 42 (2015) 1062–1074, <https://doi.org/10.1016/j.immuni.2015.05.016>.
- [140] A.E. Overacre-Delgoffe, M. Chikina, R.E. Dadey, H. Yano, E.A. Brunazzi, G. Shayan, et al., Interferon- γ drives treg fragility to promote anti-tumor immunity, *Cell* 169 (2017), <https://doi.org/10.1016/j.cell.2017.05.005> 1130–1141.e11.
- [141] F. Fallarino, U. Grohmann, C. Vacca, R. Bianchi, C. Orabona, A. Spreca, et al., T cell apoptosis by tryptophan catabolism, *Cell Death Differ.* 9 (2002) 1069–1077, <https://doi.org/10.1038/sj.cdd.4401073>.
- [142] D.I. Gabrilovich, Myeloid-derived suppressor cells, *Cancer Immunol. Res.* 5 (2017) 3–8, <https://doi.org/10.1158/2326-6066.CIR-16-0297>.
- [143] O. Draghiciu, J. Lubbers, H.W. Nijman, T. Daemen, Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy, *Oncoimmunology* 4 (2015) e954829, <https://doi.org/10.4161/21624011.2014.954829>.
- [144] P.C. Rodriguez, C.P. Hernandez, D. Quiceno, S.M. Dubinett, J. Zabaleta, J.B. Ochoa, et al., Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma, *J. Exp. Med.* 202 (2005) 931–939, <https://doi.org/10.1084/jem.20050715>.
- [145] E.M. Hanson, V.K. Clements, P. Sinha, D. Ilkovitch, S. Ostrand-Rosenberg, Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells, *J. Immunol.* 183 (2009) 937–944, <https://doi.org/10.4049/jimmunol.0804253>.
- [146] S. Nagaraj, K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, et al., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer, *Nat. Med.* 13 (2007) 828–835, <https://doi.org/10.1038/nm1609>.
- [147] B. Molon, S. Ugel, F. Del Pozzo, C. Soldani, S. Zilio, D. Avella, et al., Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells, *J. Exp. Med.* 208 (2011) 1949–1962, <https://doi.org/10.1084/jem.20101956>.
- [148] M. Llovera, J.D. Pearson, C. Moreno, V. Riveros-Moreno, Impaired response to interferon-gamma in activated macrophages due to tyrosine nitration of STAT1 by endogenous nitric oxide, *Br. J. Pharmacol.* 132 (2001) 419–426, <https://doi.org/10.1038/sj.bjp.0703838>.
- [149] F. Shojaei, X. Wu, C. Zhong, L. Yu, X.-H. Liang, J. Yao, et al., Bv8 regulates myeloid-cell-dependent tumour angiogenesis, *Nature* 450 (2007) 825–831, <https://doi.org/10.1038/nature06348>.
- [150] K. Kessenbrock, V. Plaks, Z. Werb, Matrix metalloproteinases: regulators of the tumor microenvironment, *Cell* 141 (2010) 52–67, <https://doi.org/10.1016/j.cell.2010.03.015>.
- [151] B.-Z. Qian, J.W. Pollard, Macrophage diversity enhances tumor progression and metastasis, *Cell* 141 (2010) 39–51, <https://doi.org/10.1016/j.cell.2010.03.014>.
- [152] A.J. Petty, Y. Yang, Tumor-associated macrophages: implications in cancer immunotherapy, *Immunotherapy* 9 (2017) 289–302, <https://doi.org/10.2217/imt-2016-0135>.
- [153] L. Qi, H. Yu, Y. Zhang, D. Zhao, P. Lv, Y. Zhong, et al., IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma, *Oncotarget* 7 (2016) 71673–71685, <https://doi.org/10.18632/oncotarget.12317>.
- [154] M. Genin, M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide, *BMC Cancer* (2015) 1–14, <https://doi.org/10.1186/s12885-015-1546-9>.
- [155] N. Dehne, J. Mora, D. Namgaladze, A. Weigert, B. Brüne, Science Direct Cancer cell and macrophage cross-talk in the tumor microenvironment, *Curr. Opin. Pharmacol.* 35 (2017) 12–19, <https://doi.org/10.1016/j.coph.2017.04.007>.
- [156] O.R. Colegio, N.-Q. Chu, A.L. Szabo, T. Chu, A.M. Rhebergen, V. Jairam, et al., Functional polarization of tumour-associated macrophages by tumour-derived lactic acid, *Nature* 513 (2014) 559–563, <https://doi.org/10.1038/nature13490>.
- [157] M. Yang, D. McKay, J.W. Pollard, C.E. Lewis, Diverse functions of macrophages in different tumor microenvironments, *Cancer Res.* 78 (2018) 5492–5503, <https://doi.org/10.1158/0008-5472.CAN-18-1367>.
- [158] L. Cassetta, S. Fragiogianni, A.H. Sims, A. Swierczak, L.M. Forrester, H. Zhang, et al., Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets, *Cancer Cell* (2019) 1–26, <https://doi.org/10.1016/j.ccell.2019.02.009>.
- [159] E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, A.H. Sharpe, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, *Immunity* 3 (1995) 541–547.
- [160] Y. Yu, J. Cui, Present and future of cancer immunotherapy: a tumor micro-environmental perspective (Review), *Oncol. Lett.* (2018) 1–9, <https://doi.org/10.3892/ol.2018.9219>.
- [161] L. Chen, D.B. Flies, Molecular mechanisms of T cell co-stimulation and co-inhibition, *Nat. Rev. Immunol.* 13 (2013) 227–242, <https://doi.org/10.1038/nri3405>.
- [162] E. Hui, J. Cheung, J. Zhu, X. Su, M.J. Taylor, H.A. Wallweber, et al., T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, *Science* 355 (2017) 1428–1433, <https://doi.org/10.1126/science.aaf1292>.
- [163] B. Rowshanravan, N. Halliday, D.M. Sansom, CTLA-4: a moving target in immunotherapy, *Blood* 131 (2018) 58–67, <https://doi.org/10.1182/blood-2017-06-741033>.
- [164] E.J. Wherry, J.N. Blattman, K. Murali-Krishna, R. van der Most, R. Ahmed, Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment, *J. Virol.* 77 (2003) 4911–4927, <https://doi.org/10.1128/JVI.77.8.4911-4927.2003>.
- [165] R.C. McPherson, J.E. Konkel, C.T. Prendergast, J.P. Thomson, R. Ottaviano, M.D. Leech, et al., Epigenetic modification of the PD-1 (Pdc1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy, *eLife Sci.* 3 (2014), <https://doi.org/10.7554/eLife.03416> 765–20.
- [166] K. Sakuiishi, L. Apetoh, J.M. Sullivan, B.R. Blazar, V.K. Kuchroo, A.C. Anderson, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, *J. Exp. Med.* 207 (2010) 2187–2194, <https://doi.org/10.1084/jem.20100643>.
- [167] S.C. Wei, J.H. Levine, A.P. Cogdill, Y. Zhao, N.-A.S. Anang, M.C. Andrews, et al., Distinct cellular mechanisms underlie Anti-CTLA-4 and anti-PD-1 checkpoint blockade, *Cell* 170 (2017), <https://doi.org/10.1016/j.cell.2017.07.024> 1120–1133.e17.
- [168] A. De Sousa Linares, J. Leitner, K. Grabmeier-Pfistershammer, P. Steinberger, Not all immune checkpoints are created equal, *Front. Immunol.* 9 (2018), <https://doi.org/10.3389/fimmu.2018.01909> 21–15.
- [169] A. Schietinger, P.D. Greenberg, Tolerance and exhaustion: defining mechanisms of T cell dysfunction, *Trends Immunol.* 35 (2014) 51–60, <https://doi.org/10.1016/j.it.2013.10.001>.
- [170] J. Feng, H. Yang, Y. Zhang, H. Wei, Z. Zhu, B. Zhu, et al., Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells, *Oncogene* 36 (2017) 5829–5839, <https://doi.org/10.1038/onc.2017.188>.
- [171] A. Brand, K. Singer, G.E. Koehl, M. Kolitzus, G. Schoenhammer, A. Thiel, et al., LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells, *Cell Metab.* 24 (2016) 657–671, <https://doi.org/10.1016/j.cmet.2016.08.011>.
- [172] C.-H. Chang, E.L. Pearce, Emerging concepts of T cell metabolism as a target of immunotherapy, *Nat. Immunol.* 17 (2016) 364–368, <https://doi.org/10.1038/ni.3415>.
- [173] C.-H. Chang, J.D. Curtis, L.B. Maggi Jr, B. Faubert, A.V. Villarino, D. O'Sullivan, et al., Posttranscriptional control of T cell effector function by aerobic glycolysis, *Cell* 153 (2013) 1239–1251, <https://doi.org/10.1016/j.cell.2013.05.016>.
- [174] C.M. Cham, T.F. Gajewski, Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells, *J. Immunol.* 174 (2005) 4670–4677, <https://doi.org/10.4049/jimmunol.174.8.4670>.
- [175] M. Ayers, J. Lunceford, M. Nebozhyn, E. Murphy, A. Loboda, D.R. Kaufman, et al., IFN- γ -related mRNA profile predicts clinical response to PD-1 blockade, *J. Clin. Invest.* 127 (2017) 2930–2940, <https://doi.org/10.1172/JCI91190>.
- [176] J.L. Mendoza, N.K. Escalante, K.M. Jude, J.S. Bellon, L. Su, T.M. Horton, et al., Structure of the IFN γ receptor complex guides design of biased agonists, *Nature* (2019) 1–19, <https://doi.org/10.1038/s41586-019-0988-7>.
- [177] C.S. Garriss, S.P. Arlauckas, R.H. Kohler, M.P. Trefny, S. Garren, C. Piot, et al., Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN- γ and IL-12, *Immunity* (2018) 1–22, <https://doi.org/10.1016/j.immuni.2018.09.024>.
- [178] M.P. Rubinstein, E.W. Su, S. Suriano, C.A. Cloud, K. Andrijauskaitė, P. Kesarwani, et al., Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells, *Cancer Immunol. Immunother.* 64 (2015) 539–549, <https://doi.org/10.1007/s00262-015-1655-y>.
- [179] M.L. Salem, A.N. Kadima, Y. Zhou, C.L. Nguyen, M.P. Rubinstein, M. Demcheva, et al., Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine, *J. Immunol.* 172 (2004) 5159–5167.
- [180] M.P. Rubinstein, C.A. Cloud, T.E. Garrett, C.J. Moore, K.M. Schwartz,

- C.B. Johnson, et al., Ex vivo interleukin-12-priming during CD8+ T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host, *J. Am. Coll. Surg.* 214 (2012) 700–707, <https://doi.org/10.1016/j.jamcollsurg.2011.12.034>.
- [181] L. Lin, Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN- γ , *Cancer Immunol. Immunother.* 68 (2019) 395–405, <https://doi.org/10.1007/s00262-018-2280-3>.
- [182] J. Cohen, IL-12 deaths: explanation and a puzzle, *Science* 270 (1995) 908.
- [183] J.P. Leonard, M.L. Sherman, G.L. Fisher, L.J. Buchanan, G. Larsen, M.B. Atkins, et al., Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production, *Blood* 90 (1997) 2541–2548.
- [184] J.S. Orange, T.P. Salazar-Mather, S.M. Opal, R.L. Spencer, A.H. Miller, B.S. McEwen, et al., Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids, *J. Exp. Med.* 181 (1995) 901–914.
- [185] G. Shi, C. Edelblute, S. Arpag, C. Lundberg, R. Heller, IL-12 gene electrotransfer triggers a change in immune response within mouse tumors, *Cancers* 10 (2018), <https://doi.org/10.3390/cancers10120498> 498–19.
- [186] E. Cha, A. Daud, Plasmid IL-12 electroporation in melanoma, *Hum. Vaccin. Immunother.* 8 (2012) 1734–1738, <https://doi.org/10.4161/hv.22573>.
- [187] C.-J. Wu, Y.-T. Tsai, I.-J. Lee, P.-Y. Wu, L.-S. Lu, W.-S. Tsao, et al., Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment, *Oncoimmunology* 7 (2018) 1–13, <https://doi.org/10.1080/2162402X.2018.1477459>.
- [188] D. Chinnasamy, Z. Yu, S.P. Kerkar, L. Zhang, R.A. Morgan, N.P. Restifo, et al., Local delivery of Interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice, *Clin. Cancer Res.* 18 (2012) 1672–1683, <https://doi.org/10.1158/1078-0432.CCR-11-3050>.
- [189] M. Koneru, T.J. Purdon, D. Spriggs, S. Koneru, R.J. Brentjens, IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo, *Oncoimmunology* 4 (2015) e994446–12, <https://doi.org/10.4161/2162402X.2014.994446>.
- [190] H.J. Pegram, J.C. Lee, E.G. Hayman, G.H. Imperato, T.F. Tedder, M. Sadelain, et al., Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, *Blood* 119 (2012) 4133–4141, <https://doi.org/10.1182/blood-2011-12-400044>.
- [191] S.P. Kerkar, P. Muranski, A. Kaiser, A. Boni, L. Sanchez-Perez, Z. Yu, et al., Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts, *Cancer Res.* 70 (2010) 6725–6734, <https://doi.org/10.1158/0008-5472.CAN-10-0735>.
- [192] L. Zhang, S.P. Kerkar, Z. Yu, Z. Zheng, S. Yang, N.P. Restifo, et al., Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment, *Mol. Ther.* 19 (2011) 751–759, <https://doi.org/10.1038/mt.2010.313>.
- [193] M. Chmielewski, C. Kopecky, A.A. Hombach, H. Abken, IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression, *Cancer Res.* 71 (2011) 5697–5706, <https://doi.org/10.1158/0008-5472.CAN-11-0103>.
- [194] A. Alsaieedi, A. Holler, P. Veliça, G. Bendle, H.J. Stauss, Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells, *Oncoimmunology* 8 (2019) 1–11, <https://doi.org/10.1080/2162402X.2018.1542917>.
- [195] O.O. Yeku, T.J. Purdon, M. Koneru, D. Spriggs, R.J. Brentjens, Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment, *Sci. Rep.* (2017) 1–14, <https://doi.org/10.1038/s41598-017-10940-8>.
- [196] M.O. Kilinc, K.S. Aulakh, R.E. Nair, S.A. Jones, P. Alard, M.M. Kosiewicz, et al., Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors, *J. Immunol.* 177 (2006) 6962–6973, <https://doi.org/10.4049/jimmunol.177.10.6962>.
- [197] N.K. Egilmez, J.L. Harden, L.P. Virtuoso, R.A. Schwendener, M.O. Kilinc, Nitric oxide short-circuits interleukin-12-mediated tumor regression, *Cancer Immunol. Immunother.* 60 (2011) 839–845, <https://doi.org/10.1007/s00262-011-0998-2>.
- [198] F. Eckert, I. Jelas, M. Oehme, S.M. Huber, K. Sonntag, C. Welker, et al., Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo, *Oncoimmunology* 6 (2017) 1–12, <https://doi.org/10.1080/2162402X.2017.1323161>.
- [199] F. Eckert, U.S. Gaip, G. Niedermann, M. Hettich, K. Schilbach, S.M. Huber, et al., Beyond checkpoint inhibition - Immunotherapeutic strategies in combination with radiation, *Clin Transl Radiat Oncol.* 2 (2017) 29–35, <https://doi.org/10.1016/j.ctro.2016.12.006>.
- [200] J. Strauss, C.R. Heery, J.W. Kim, C. Jochems, R.N. Donahue, A.S. Montgomery, et al., First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors, *Clin. Cancer Res.* 25 (2019) 99–109, <https://doi.org/10.1158/1078-0432.CCR-18-1512>.